Selective serotonin reuptake inhibitor is more likely to induce sexual dysfunction than mirtazapine in treating depression.
- Author:
Zheng-xin CHEN
1
;
He-qiu WANG
;
Wei-dong JIN
Author Information
- Publication Type:Journal Article
- MeSH: Antidepressive Agents, Tricyclic; adverse effects; Depressive Disorder; drug therapy; Erectile Dysfunction; chemically induced; Humans; Male; Mianserin; adverse effects; analogs & derivatives; Serotonin Uptake Inhibitors; adverse effects
- From: National Journal of Andrology 2008;14(10):896-899
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the incidences of sexual dysfunction induced by mirtazapine and SSRI in the treatment of patients with depression.
METHODSUsing key-word retrieval from the compact disks of the Chinese biological medicine (CBM) data base, we analyzed the rates of sexual dysfunction from the published clinical control trials on depression treated with mirtazapine and SSRI by applying the fixed effects model (FEM) of evidence-based medicine (EBM).
RESULTSAmong 1108 cases in 14 studies, there were 5 cases of mirtazapine-induced and 106 cases of SSRI-induced sexual dysfunction, accounting for 0.90% and 19.2% respectively, OR = 0.07 (95% CI: 0.04-0.14), Z = 8.03, P < 0.01.
CONCLUSIONSSRI is far more likely to induce sexual dysfunction than mirtazapine in the treatment of depression.
